ORKA
Oruka Stock Jumps 12.7% on Positive Week 16 Psoriasis Trial Data for ORKA-001
The 61% PASI 100 response in the high-dose group matched results from the earlier EVERLAST-A trial, and the company plans Phase 3 trials in the first half of 2027.
Oruka Therapeutics ORKA
Oruka Therapeutics, Inc. · Nasdaq · Pharmaceutical Preparations
$95.97+0.17%close on Oct. 28, 2026 · volume 798K · Yahoo Finance
Price, last 47 sessions
Our coverage
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 20, 2026 | Paul T. Quinlan General Counsel | Sold 10b5-1 plan | 9,000 | $78.53 $74.90-$79.49 | $706,735 |
| Oct. 15, 2026 | Joana Goncalves Chief Medical Officer | Sold 10b5-1 plan | 7,000 | $74.81 $73.89-$77.71 | $523,648 |
| Oct. 12, 2026 | Arjun Agarwal Senior Vice President, Finance | Sold 10b5-1 plan | 9,999 | $80.60 $80.03-$82.84 | $805,889 |
| Oct. 1, 2026 | Lawrence Otto Klein Chief Executive Officer, director | Sold 10b5-1 plan | 25,000 | $83.62 $83.40-$84.78 | $2.09 million |
| Sept. 21, 2026 | Arjun Agarwal Senior Vice President, Finance | Sold 10b5-1 plan | 533 | $95.75 | $51,035 |
| Sept. 21, 2026 | Paul T. Quinlan General Counsel | Sold 10b5-1 plan | 10,000 | $93.64 $92.37-$95.31 | $936,417 |
| Sept. 15, 2026 | Joana Goncalves Chief Medical Officer | Sold 10b5-1 plan | 7,947 | $92.38 $91.10-$95.71 | $734,145 |
| Sept. 15, 2026 | Arjun Agarwal Senior Vice President, Finance | Sold 10b5-1 plan | 560 | $95.71 | $53,598 |
| Sept. 15, 2026 | Lawrence Otto Klein Chief Executive Officer, director | Sold | 2,452 | $95.71 | $234,681 |
| Sept. 15, 2026 | Paul T. Quinlan General Counsel | Sold | 1,039 | $95.71 | $99,443 |
| Sept. 15, 2026 | Laura Lee Sandler Chief Operating Officer | Sold | 906 | $95.71 | $86,713 |
| Sept. 11, 2026 | Arjun Agarwal Senior Vice President, Finance | Sold 10b5-1 plan | 9,459 | $92.23 $91.11-$94.02 | $872,412 |
Latest 12 of 17. Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 26 →Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedOruka Therapeutics Reports Positive Week 16 EVERLAST-B Results for ORKA-001: 61% PASI 100 at 600 mg vs. 0% Placebo